Mabpharm Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Hao Wang

Amministratore delegato

CN¥5.6m

Compenso totale

Percentuale dello stipendio del CEO	19.1%
Mandato del CEO	6.3yrs
Proprietà del CEO	n/a
Durata media del management	6.3yrs
Durata media del Consiglio di amministrazione	4.1yrs

Aggiornamenti recenti sulla gestione

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Jun 14

Recent updates

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Jun 14

More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Jan 24

Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Apr 28

Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

Mar 03

We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

Jan 27

Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

Dec 09

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Hao Wang rispetto agli utili di Mabpharm?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-CN¥207m
Mar 31 2024	n/a	n/a	-CN¥208m
Dec 31 2023	CN¥6m	CN¥1m	-CN¥209m
Sep 30 2023	n/a	n/a	-CN¥202m
Jun 30 2023	n/a	n/a	-CN¥194m
Mar 31 2023	n/a	n/a	-CN¥202m
Dec 31 2022	CN¥3m	CN¥1m	-CN¥211m
Sep 30 2022	n/a	n/a	-CN¥237m
Jun 30 2022	n/a	n/a	-CN¥263m
Mar 31 2022	n/a	n/a	-CN¥278m
Dec 31 2021	CN¥5m	CN¥1m	-CN¥292m

Compensazione vs Mercato: La retribuzione totale di Hao ($USD 772.79K ) è superiore alla media delle aziende di dimensioni simili nel mercato Hong Kong ($USD 347.88K ).

Compensazione vs guadagni: La retribuzione di Hao è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Hao Wang (55 yo)

6.3yrs

Mandato

CN¥5,596,000

Compensazione

Dr. Hao Wang serves as Chief Executive Officer and Executive Director at Mabpharm Limited since October 28, 2020 and July 20, 2018 respectively and also serves as Chief Scientist since August 2018. Dr. Wan...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Hao Wang	Chief Scientist	6.3yrs	CN¥5.60m	Nessun dato
Jing Tao	VP & Executive Director	no data	CN¥1.54m	Nessun dato
Sheng Hou	VP & Executive Director	less than a year	CN¥70.00k	Nessun dato
Weizhu Qian	VP & Executive Director	less than a year	CN¥445.00k	Nessun dato
Yunfeng Li	VP, Joint Company Secretary & Executive Director	6.3yrs	CN¥1.58m	Nessun dato
Jing Li	Vice President	6.3yrs	CN¥1.40m	Nessun dato
Ho Yin Tsang	Joint Company Secretary	no data	Nessun dato	Nessun dato

6.3yrs

Durata media

48yo

Età media

Gestione esperta: Il team dirigenziale di 2181 è esperto e expertise (durata media dell'incarico 6.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Hao Wang	Chief Scientist	6.3yrs	CN¥5.60m	Nessun dato
Jing Tao	VP & Executive Director	4.1yrs	CN¥1.54m	Nessun dato
Sheng Hou	VP & Executive Director	less than a year	CN¥70.00k	Nessun dato
Weizhu Qian	VP & Executive Director	less than a year	CN¥445.00k	Nessun dato
Yunfeng Li	VP, Joint Company Secretary & Executive Director	6.3yrs	CN¥1.58m	Nessun dato
Shuge Jiao	Non-Executive Chairman	6.3yrs	Nessun dato	Nessun dato
Liangzhong Guo	Independent Non-Executive Director	6.3yrs	CN¥108.00k	Nessun dato
Yanyun Zhang	Independent Non-Executive Director	6.3yrs	CN¥108.00k	Nessun dato
Louis Ho Ming	Independent Non-Executive Director	2.4yrs	CN¥108.00k	Nessun dato
Jialin Cen	Non-Executive Director	less than a year	Nessun dato	Nessun dato
Qian Tao	Independent Non-Executive Director	less than a year	Nessun dato	Nessun dato

4.1yrs

Durata media

51yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 2181 sono considerati esperti (durata media dell'incarico 4.1 anni).

Mabpharm Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Mabpharm Limited Announces Resignation of Li Yunfeng as Chief Financial Officer

Mabpharm Limited Announces Resignation of Li Yunfeng as Chief Financial Officer

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Mabpharm Limited, Annual General Meeting, Jun 21, 2024

Mabpharm Limited Announces Director Changes

Less than half of directors are independent

Recent updates

First half 2024 earnings released: CN¥0.024 loss per share (vs CN¥0.024 loss in 1H 2023)

Mabpharm Limited to Report First Half, 2024 Results on Aug 28, 2024

Mabpharm Limited Announces Resignation of Li Yunfeng as Chief Financial Officer

Mabpharm Limited Announces Resignation of Li Yunfeng as Chief Financial Officer

Mabpharm Limited Announces Approval from the Ministry of Health of Peru on the New Drug Application of CMAB008 (Infliximab for Injection)

Simcere Zaiming and Mabpharm Limited Announce Approval of Cetuximab Beta in China by the NMPA

Simcere Pharmaceutical Group Limited and Mabpharm Limited Announce Approval on the Marketing of ENLITUO in China by the National Medical Products Administration of China

Shareholders May Be A Bit More Conservative With Mabpharm Limited's (HKG:2181) CEO Compensation For Now

Mabpharm Limited, Annual General Meeting, Jun 21, 2024

Full year 2023 earnings released: CN¥0.05 loss per share (vs CN¥0.051 loss in FY 2022)

Mabpharm Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

More Unpleasant Surprises Could Be In Store For Mabpharm Limited's (HKG:2181) Shares After Tumbling 41%

Mabpharm Limited Announces Director Changes

First half 2023 earnings released: CN¥0.024 loss per share (vs CN¥0.028 loss in 1H 2022)

Mabpharm Limited to Report First Half, 2023 Results on Aug 25, 2023

Full year 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.071 loss in FY 2021)

Less than half of directors are independent

Mabpharm (HKG:2181) Is Making Moderate Use Of Debt

Mabpharm Limited to Report First Half, 2022 Results on Aug 26, 2022

Mabpharm Limited Approves the Clinical Trial Application of CMAB015 for the Treatment of Psoriasis and Ankylosing Spondylitis

Mabpharm Limited Announces Approval by National Medical Products Administration of China for the Clinical Trial Application of Biological Class I New Drug Cmab017

Less than half of directors are independent

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

Mabpharm Limited Announces Approval of Clinical Trial Application of CMAB807X by the National Medical Products Administration of China

Here's Why We're Watching Mabpharm's (HKG:2181) Cash Burn Situation

First half 2021 earnings released: CN¥0.035 loss per share (vs CN¥0.013 loss in 1H 2020)

Here's Why We're Not Too Worried About Mabpharm's (HKG:2181) Cash Burn Situation

Mabpharm Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: HK$1.18

Did You Miss Mabpharm's (HKG:2181) 14% Share Price Gain?

We're Not Very Worried About Mabpharm's (HKG:2181) Cash Burn Rate

New 90-day low: HK$1.08

Do Insiders Own Lots Of Shares In Mabpharm Limited (HKG:2181)?

New 90-day low: HK$1.14

Mabpharm Limited Announces CEO Changes

New 90-day low: HK$1.15

Mabpharm Limited to Report First Half, 2020 Results on Aug 26, 2020

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media